ClinicalTrials.gg
Drug

Pemigatinib clinical trials

Also written INCB054828 and Pemazyre.

studies test it
46
open now
19
in phase 3
1
first study started
2015

How each study uses pemigatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the pemigatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
17 Apr 2020 · PEMAZYRE · NDA 213736 (FDA, Drugs@FDA)
European Union
26 Mar 2021 · Pemazyre · EMEA/H/C/005266 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pemigatinib
41
Pemigatinib Pill
2

Brand

Pemazyre
17

Development codes

INCB054828
21

Other names

FGFR inhibitor INCB054828
1

Studies by the year they started

46 studies that test it; most in 2022 (8)

Studies that test pemigatinib, by start year
YearStudies
20151
20161
20174
20181
20194
20206
20216
20228
20233
20245
20253
20264

Who runs them

Industry 16 · Other 30

Incyte Corporation (13) · Academic and Community Cancer Research United (2) · Innovent Biologics (Suzhou) Co. Ltd. (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of Utah (1) · Hoffmann-La Roche (1)

Often tested with

Tested in the same studies.

Durvalumab (4) · Pertuzumab (3) · Atezolizumab (3) · Olaparib (2) · Ivosidenib (2) · Alectinib (2) · Cobimetinib (2) · HhAntag691 (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5

Studies that test pemigatinib.

Studies

Open first, then newest update. How each study uses pemigatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 46

See all 46 studies that test pemigatinib →

Given beside what is tested · 3 — pemigatinib is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call pemigatinib · ClinicalTrials.gg INT001280

  • MeSH (NLM) C000705477pemigatinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) Y6BX7BL23KPEMIGATINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2359268One source FDA
  • Wikidata Q96398739pemigatinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C121553PemigatinibOne source FDA
  • DrugBank DB15102One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.